Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $10
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $17 to $10.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
68 Biggest Movers From Yesterday
Gainers
ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday.
Mid-Afternoon Market Update: Dow Gains 2%; SAB Biotherapeutics Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 2% on Wednesday.
